{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:29:12Z","timestamp":1787232552291,"version":"build-2736575974"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14893-5","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:52:41Z","timestamp":1783439561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structural drivers of drug shortages and market withdrawal: a longitudinal analysis of the Romanian pharmaceutical market"],"prefix":"10.1186","volume":"26","author":[{"given":"Oana-Teodora","family":"Chirac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana-Elena","family":"T\u0103erel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Dinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ancuceanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"2","key":"14893_CR1","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.sapharm.2025.10.008","volume":"22","author":"N Cornelissen","year":"2026","unstructured":"Cornelissen N, Zielhuis SW, van den Bemt PMLA, van den Bemt BJF. Causes and management of drug shortages: a scoping review. Res Soc Adm Pharm [Internet]. 2026, Feb;22(2):232\u201353. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741125004760.","journal-title":"Res Soc Adm Pharm"},{"issue":"1","key":"14893_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.37897\/RJPhP.2022.1.4","volume":"15","author":"A-V Focsa","year":"2022","unstructured":"Focsa A-V, Birsan M, Dragan M, Stan RT, Mircea C, Stan CD. The impact of medicines shortages on pharmaceutical practice. Ro J Pharm Pract. 2022, Mar, 31;15(1):14\u201318. https:\/\/doi.org\/10.37897\/RJPhP.2022.1.4.","journal-title":"Ro J Pharm Pract"},{"key":"14893_CR3","doi-asserted-by":"publisher","unstructured":"Santhireswaran A, Chaudhry S, Ho M, Fuller K, Gaudette E, Burry L, et al. Impact of supply chain disruptions and drug shortages on drug utilization: a scoping review. Pharmacoepidemiol Drug [Internet]. 2025, Jul, 2;34(7). Available from: https:\/\/doi.org\/10.1002\/pds.70178.","DOI":"10.1002\/pds.70178"},{"key":"14893_CR4","doi-asserted-by":"crossref","unstructured":"Ros\u00e1rio A, Hank\u00f3 B, Zelk\u00f3 R. Managing drug shortages in pediatric care. Front Pharmacol [Internet]. 2024, Jun, 25;15. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1416029\/full.","DOI":"10.3389\/fphar.2024.1416029"},{"key":"14893_CR5","unstructured":"Chapman S, Dedet G LR. Shortages of medicines in OECD countries [Internet]. OECD Health Work Papers. 2022 [cited 2025 Sep 29];137. Available from: https:\/\/www.oecd.org\/en\/publications\/shortages-of-medicines-in-oecd-countries_b5d9e15d-en.html."},{"issue":"1","key":"14893_CR6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1186\/s12913-021-06812-7","volume":"21","author":"M Atif","year":"2021","unstructured":"Atif M, Sehar A, Malik I, Mushtaq I, Ahmad N, Z-U-D B. What impact does medicines shortages have on patients? A qualitative study exploring patients\u2019 experience and views of healthcare professionals. BMC Health Serv Res. 2021, Dec, 17;21(1):827.","journal-title":"BMC Health Serv Res"},{"key":"14893_CR7","doi-asserted-by":"publisher","first-page":"119171","DOI":"10.1016\/j.ijpharm.2020.119171","volume":"579","author":"UM Musazzi","year":"2020","unstructured":"Musazzi UM, Di Giorgio D, Minghetti P. New regulatory strategies to manage medicines shortages in Europe. Int J Multiling Pharm. 2020, Apr;579:119171. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119171.","journal-title":"Int J Multiling Pharm"},{"issue":"7","key":"14893_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2146\/ajhp120563","volume":"70","author":"A McBride","year":"2013","unstructured":"McBride A, Holle LM, Westendorf C, Sidebottom M, Griffith N, Muller RJ, et al. National survey on the effect of oncology drug shortages on cancer care. Am J Health-System Pharm [Internet]. 2013, Apr, 1;70(7):609\u201317. Available from: https:\/\/academic.oup.com\/ajhp\/article\/70\/7\/609\/5112445.","journal-title":"Am J Health-System Pharm"},{"issue":"1","key":"14893_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s12028-019-00730-7","volume":"32","author":"SL Clark","year":"2020","unstructured":"Clark SL, Levasseur-Franklin K, Pajoumand M, Barra M, Armahizer M, Patel D V, et al. Collaborative management strategies for drug shortages in neurocritical care. Neurocrit Care [Internet]. 2020, Feb, 10;32(1):226\u201337. Available from: https:\/\/doi.org\/10.1007\/s12028-019-00730-7.","journal-title":"Neurocrit Care"},{"issue":"3","key":"14893_CR10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.pharma.2024.12.001","volume":"83","author":"I B\u00e9atrix","year":"2025","unstructured":"B\u00e9atrix I, Bonnabry E, Atkinson S, Lebel D, Bussi\u00e8res J-F. Drug shortages in Canada, 2019\u20132023: a descriptive study. Ann Pharmaceutiques Fran\u00e7aises [Internet]. 2025, May;83(3):505\u201313. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000345092400172X.","journal-title":"Ann Pharmaceutiques Fran\u00e7aises"},{"issue":"3","key":"14893_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s41669-019-0120-9","volume":"3","author":"S Vogler","year":"2019","unstructured":"Vogler S, Schneider P, Zimmermann N. Evolution of average European medicine prices: implications for the methodology of external price referencing. Pharmacoeconomics Open [Internet]. 2019, Sep, 5;3(3):303\u201309. Available from: https:\/\/doi.org\/10.1007\/s41669-019-0120-9.","journal-title":"Pharmacoeconomics Open"},{"issue":"3","key":"14893_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.mayocp.2013.11.014","volume":"89","author":"ER Fox","year":"2014","unstructured":"Fox ER, Sweet B V, Jensen V. Drug shortages: a complex Health care crisis. Mayo Clin Proc [Internet]. 2014, Mar;89(3):361\u201373. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619613010434.","journal-title":"Mayo Clin Proc"},{"key":"14893_CR13","doi-asserted-by":"crossref","unstructured":"Calvo M, Tirapu B, Larr\u00e1yoz B, Sarobe M. Drug shortages: a critical challenge in the era of automated intravenous compounding. Eur J Hosp Pharm [Internet]. 2025. Available from: ejhpharm-2025\u2013004607. 10.1136\/ejhpharm-2025-004607.","DOI":"10.1136\/ejhpharm-2025-004607"},{"key":"14893_CR14","doi-asserted-by":"crossref","unstructured":"Acosta A, Vanegas EP, Rovira J, Godman B, Bochenek T. Medicine shortages: gaps between countries and global perspectives. Front Pharmacol [Internet]. 2019, Jul, 19;10. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00763\/full.","DOI":"10.3389\/fphar.2019.00763"},{"issue":"1","key":"14893_CR15","first-page":"23","volume":"79","author":"V Goncette","year":"2024","unstructured":"Goncette V, Radermecker R. M\u00e9dicaments indisponibles: une fatalit\u00e9? Rev Med Liege [Internet]. 2024, Jan;79(1):23\u201328. Available from: https:\/\/rmlg.uliege.be\/article\/3849?lang=en.","journal-title":"Rev Med Liege"},{"issue":"11","key":"14893_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.4066\/AMJ.2013.1869","volume":"6","author":"W Lipworth","year":"2013","unstructured":"Lipworth W. Why drug shortages are an ethical issue. AMJ. 2013, Dec, 1;6(11):556\u201359. https:\/\/doi.org\/10.4066\/AMJ.2013.1869.","journal-title":"AMJ"},{"key":"14893_CR17","unstructured":"The European Parliament and the council of the European union. regulation (EU) 2022\/123 of the European Parliament and of the council of 25 January 2022 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices (text with EEA relevance) [Internet]. 2022 Jan [cited 2025 May 2]. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32022R0123."},{"issue":"10223","key":"14893_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0140-6736(20)30354-8","volume":"395","author":"R Hyde","year":"2020","unstructured":"Hyde R. Europe faces worsening medicine shortages. Lancet [Internet]. 2020, Feb;395(10223):481\u201382. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673620303548.","journal-title":"Lancet"},{"issue":"10","key":"14893_CR19","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1111\/bcp.15853","volume":"89","author":"JK Aronson","year":"2023","unstructured":"Aronson JK, Heneghan C, Ferner RE. Drug shortages. Part 2: trends, causes and solutions. Brit J Clin Pharma. 2023, Oct, 6;89(10):2957\u201363. https:\/\/doi.org\/10.1111\/bcp.15853.","journal-title":"Brit J Clin Pharma"},{"key":"14893_CR20","unstructured":"World Health Organization. Medicines shortages: global approaches to addressing shortages of essential medicines in health systems. WHO Drug Inf [Internet]. 2016;30(2):180\u201385. Available from: https:\/\/iris.who.int\/handle\/10665\/331028."},{"key":"14893_CR21","unstructured":"Office of the Assistant Secretary for Planning and Evaluation. Impact of drug shortages on patients in the United States: a case study of three drugs [Internet]. 2024. Available from: https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/8e13b6ed2d2c34ba1b8188ec6ecaa2a2\/impact-drug-shortage-on-cancer.pdf. U.S. Department of Health and Human Services. Washington, DC."},{"issue":"14","key":"14893_CR22","doi-asserted-by":"publisher","first-page":"04225","DOI":"10.7189\/jogh.14.04225","volume":"14","author":"T Huang","year":"2024","unstructured":"Huang T, Bai L, Li H, Li H, Wang Z, Shi L, et al. Trends of drug shortages in China from 2018 to 2020: a retrospective observational study. J Glob Health [Internet]. 2024, Oct;14(14):04225. Available from: https:\/\/doi.org\/10.7189\/jogh.14.04225.","journal-title":"J Glob Health"},{"issue":"1","key":"14893_CR23","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1186\/s12889-024-19361-5","volume":"24","author":"Y Lan","year":"2024","unstructured":"Lan Y, Lin X, Chen Q, Wang L, Sun L, Huang Z. Drug supply and assurance: a cross-sectional study of drug shortage monitoring varieties in China. BMC Public Health [Internet]. 2024, Jul, 30;24(1):2048. Available from: https:\/\/doi.org\/10.1186\/s12889-024-19361-5.","journal-title":"BMC Public Health"},{"key":"14893_CR24","doi-asserted-by":"publisher","first-page":"113926","DOI":"10.1016\/j.socscimed.2021.113926","volume":"278","author":"V Chebolu-Subramanian","year":"2021","unstructured":"Chebolu-Subramanian V, Sundarraj RP. Essential medicine shortages, procurement process and supplier response: a normative study across Indian states. Soc Sci Med [Internet]. 2021, Jun;278:113926. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0277953621002586.","journal-title":"Soc. Sci. Med"},{"issue":"10","key":"14893_CR25","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1111\/bcp.15842","volume":"89","author":"JK Aronson","year":"2023","unstructured":"Aronson JK, Heneghan C, Ferner RE. Drug shortages. Part 1. Definitions and harms. Brit J Clin Pharma. 2023, Oct, 6;89(10):2950\u201356. https:\/\/doi.org\/10.1111\/bcp.15842.","journal-title":"Brit J Clin Pharma"},{"issue":"1","key":"14893_CR26","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1186\/s12913-022-08309-3","volume":"22","author":"R Ravela","year":"2022","unstructured":"Ravela R, Lyles A, Airaksinen M. National and transnational drug shortages: a quantitative descriptive study of public registers in Europe and the USA. BMC Health Serv Res [Internet]. 2022, Dec, 22;22(1):940. Available from: https:\/\/doi.org\/10.1186\/s12913-022-08309-3.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"14893_CR27","doi-asserted-by":"publisher","first-page":"100748","DOI":"10.1016\/j.pursup.2022.100748","volume":"28","author":"A Spieske","year":"2022","unstructured":"Spieske A, Gebhardt M, Kopyto M, Birkel H. Improving resilience of the healthcare supply chain in a pandemic: evidence from Europe during the COVID-19 crisis. J Educ Chang Purchasing Supply Manag [Internet]. 2022, Dec;28(5):100748. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1478409222000036.","journal-title":"J Educ Chang Purchasing Supply Manag"},{"key":"14893_CR28","unstructured":"McGeeney JD, McAden E, Sertkaya A. Analysis of drug shortages, 2018-2023. Prep by East Res group, inc off ofthe assist secr plan eval (ASPE). Usdepartment heal hum serv [Internet]. 2025, Available from: https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/efa332939da2064fa2c132bb8e842bb5\/Drug_Shortages_Data_Brief_Final_2025.01.10.pdf."},{"key":"14893_CR29","doi-asserted-by":"publisher","unstructured":"Beck M, Buckley J. Managing pharmaceutical shortages during the COVID pandemic: an exploratory analysis of European collective and national government responses. J Med Access [Internet]. 2022, Jan, 17;6. Available from: https:\/\/doi.org\/10.1177\/27550834221123425.","DOI":"10.1177\/27550834221123425"},{"issue":"10378","key":"14893_CR30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0140-6736(22)01840-2","volume":"401","author":"T Lefran\u00e7ois","year":"2023","unstructured":"Lefran\u00e7ois T, Malvy D, Atlani-Duault L, Benamouzig D, Druais P-L, Yazdanpanah Y, et al. After 2 years of the COVID-19 pandemic, translating one Health into action is urgent. Lancet. 2023, Mar;401(10378):789\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(22)01840-2.","journal-title":"Lancet"},{"key":"14893_CR31","first-page":"537","volume-title":"Strategica: international academic conference","author":"A-M Giurea","year":"2017","unstructured":"Giurea A-M, Lolea I-C. Analytical review of the pharmaceutical industry in Romania. In: P\u00eenzaru F, Zbuchea A, Br\u0103tianu C, V\u0103t\u0103m\u0103nescu E-M, Mitan A, editors. Strategica: international academic conference. 5th. Bucharest: Tritonic Publishing House; 2017. p. 537\u201349.","edition":"5th"},{"issue":"1","key":"14893_CR32","first-page":"869","volume":"23","author":"N Asalo\u0219","year":"2023","unstructured":"Asalo\u0219 N, Roman C, Bostan P. Pharma sector under the influence of the parafiscal mechanism: clawback tax. Ovidius Univ Ann Econ Sci Ser [Internet]. 2023;23(1):869\u201375. Available from: https:\/\/ideas.repec.org\/a\/ovi\/oviste\/vxxiiiy2023i1p869-875.html.","journal-title":"Ovidius Univ Ann Econ Sci Ser"},{"key":"14893_CR33","doi-asserted-by":"crossref","unstructured":"Radu C, Serban DE, Chiriac ND. Delayed access to innovative medicines in Romania: a comprehensive analysis of the reimbursement processes (2015\u20132024). Front Public Health [Internet]. 2025, May, 30;13. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1592419\/full.","DOI":"10.3389\/fpubh.2025.1592419"},{"key":"14893_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.vhri.2017.11.003","volume":"16","author":"C-P Radu","year":"2018","unstructured":"Radu C-P, Pana BC, Furtunescu FL. Drug policy in Romania. Value Heal Reg issues [Internet]. Value Health Reg Issues. 2018, Sep;16:28\u201332. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109918300529.","journal-title":"Value Health Reg Issues"},{"key":"14893_CR35","unstructured":"Chirac O, T\u0103erel A-E, Dinu M, Ancuceanu R. Supply chain vulnerability and regulatory Gaps: an Evaluation of drug shortages in the Romanian pharmaceutical market (2008-2024). Farmacia. 2026;74(7)."},{"key":"14893_CR36","unstructured":"National Agency for Medicines and Medical Devices of Romania. Drug shortage notifications [Internet]. 2026 [cited 2026 Feb 8]. https:\/\/www.anm.ro\/en\/medicamente-de-uz-uman\/autorizare-medicamente\/notificari-discontinuitate-medicamente\/."},{"key":"14893_CR37","unstructured":"Ministry of Health of Romania. Order of the minister of Health No. 85 of February 7. 2013. Published in the Official Gazette No. 93 of February 14, 2013."},{"key":"14893_CR38","unstructured":"Ministry of Health of Romania. National Public Catalog of Maximum Prices for Medicines for Human Use [Internet]. 2026 [cited 2026 Jan 16]. https:\/\/ms.ro\/ro\/minister\/organizare\/directia-politica-medicamentului-si-a-dispozitivelor-medicale\/preturi-medicamente\/catalogul-public-national-al-preturilor-maximale-ale-medicamentelor-de-uz-uman\/."},{"key":"14893_CR39","unstructured":"R Core Team. R: a language and environment for statistical Computing. R Foundation Stat Comput [Internet]. 2025. Available from: https:\/\/www.r-project.org\/."},{"key":"14893_CR40","unstructured":"Ministry of Health of Romania. Ministerial Order No. 368 of March 28, 2017, for the approval of the rules on the calculation and approval procedure of the maximum prices of medicinal products for human use. Official monitor of Romania No. 133\/14.02. 2025."},{"issue":"4","key":"14893_CR41","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/biomet\/asx046","volume":"104","author":"EC Kenne Pagui","year":"2017","unstructured":"Kenne Pagui EC, Salvan A, Sartori N. Median bias reduction of maximum likelihood estimates. Biometrika [Internet]. 2017, Dec, 1;104(4):923\u201338. Available from: http:\/\/academic.oup.com\/biomet\/article\/104\/4\/923\/4103602.","journal-title":"Biometrika"},{"key":"14893_CR42","doi-asserted-by":"crossref","unstructured":"Kosmidis I, Kenne Pagui EC. brglm2: bias reduction in generalized linear models [Internet]. CRAN: Contributed Packages. 2017. Available from: https:\/\/cran.r-project.org\/package=brglm2.","DOI":"10.32614\/CRAN.package.brglm2"},{"key":"14893_CR43","doi-asserted-by":"crossref","unstructured":"Wickham H, Fran\u00e7ois R, Henry L, M\u00fcller K, Vaughan D. Dplyr: a grammar of data manipulation [Internet]. CRAN: Contributed Packages. 2014. Available from: https:\/\/cran.r-project.org\/package=dplyr.","DOI":"10.32614\/CRAN.package.dplyr"},{"key":"14893_CR44","unstructured":"Wickham H. Elegant graphics for data analysis [Internet]. Springer-Verlag New York. 2016 [cited 2026 Jan 29]. https:\/\/ggplot2.tidyverse.org."},{"key":"14893_CR45","doi-asserted-by":"crossref","unstructured":"Robinson D, Hayes A, Couch S, Hvitfeldt E. Broom: convert statistical objects into Tidy Tibbles [Internet]. CRAN: Contributed Packages. 2014. Available from: https:\/\/cran.r-project.org\/package=broom.","DOI":"10.32614\/CRAN.package.broom"},{"key":"14893_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/b97626","volume-title":"Statistical analysis of financial data in S-Plus","author":"WN Venables","year":"2004","unstructured":"Venables WN, Ripley BD. Statistical analysis of financial data in S-Plus [Internet]. New York: Springer-Verlag; 2004. (Springer Texts in Statistics). Available from: https:\/\/doi.org\/10.1007\/b97626."},{"issue":"3","key":"14893_CR47","first-page":"7","volume":"2","author":"A Zeileis","year":"2002","unstructured":"Zeileis A, Hothorn T. Diagnostic checking in regression relationships. R News [Internet]. 2002;2(3):7\u201310. Available from: https:\/\/journal.r-project.org\/articles\/RN-2002-018\/RN-2002-018.pdf.","journal-title":"R News"},{"key":"14893_CR48","doi-asserted-by":"crossref","unstructured":"Zeileis A. Object-oriented computation of sandwich estimators. J. Stat. Soft. [Internet]. 2006;16(9). Available from: http:\/\/www.jstatsoft.org\/v16\/i09\/.","DOI":"10.18637\/jss.v016.i09"},{"key":"14893_CR49","doi-asserted-by":"crossref","unstructured":"Kleiber C, Zeileis A. AER: applied econometrics with R [Internet]. CRAN: Contributed Packages; 2008. Available from: https:\/\/cran.r-project.org\/package=AER.","DOI":"10.32614\/CRAN.package.AER"},{"issue":"1","key":"14893_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v103.i01","volume":"103","author":"V Arel-Bundock","year":"2022","unstructured":"Arel-Bundock V. Modelsummary: data and model summaries in R. J. Stat. Soft. [Internet]. 2022;103(1):1\u201323. Available from: https:\/\/www.jstatsoft.org\/v103\/i01\/.","journal-title":"J. Stat. Soft."},{"key":"14893_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data: extending the Cox model [Internet]. (Statistics for Biology and Health)","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model [Internet]. (Statistics for Biology and Health). New York, NY: Springer New York; 2000. Available from: https:\/\/doi.org\/10.1007\/978-1-4757-3294-8."},{"issue":"1","key":"14893_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinf [Internet]. 2011, Dec, 17;12(1):77. Available from: https:\/\/doi.org\/10.1186\/1471-2105-12-77.","journal-title":"BMC Bioinf"},{"key":"14893_CR53","volume-title":"Companion to applied regression","author":"J Fox","year":"2019","unstructured":"Fox J, Weisberg S. Companion to applied regression. CRAN: Contributed Packages; 2019."},{"key":"14893_CR54","doi-asserted-by":"publisher","unstructured":"Callaway Kim K, Rothenberger SD, Tadrous M, Hernandez I, Gellad WF, Devine JW, et al. Drug shortages prior to and during the COVID-19 pandemic. JAMA Netw Open. 2024, Apr, 5;7(4):E244246. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.4246.","DOI":"10.1001\/jamanetworkopen.2024.4246"},{"issue":"1","key":"14893_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMp1112633","volume":"109","author":"RB Melchert","year":"2012","unstructured":"Melchert RB, Fincham JE. Escalating medication shortages: a public health and patient care crisis. Mo Med [Internet]. 2012;109(1):20\u201323. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22428441.","journal-title":"Mo Med"},{"key":"14893_CR56","doi-asserted-by":"publisher","first-page":"105030","DOI":"10.1016\/j.healthpol.2024.105030","volume":"143","author":"S Vogler","year":"2024","unstructured":"Vogler S. Tackling medicine shortages during and after the COVID-19 pandemic: compilation of governmental policy measures and developments in 38 countries. Health policy (New York) [Internet]. Health Policy (New Y). 2024, May;143:105030. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016885102400040X.","journal-title":"Health Policy (New Y)"},{"issue":"1","key":"14893_CR57","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1186\/s12889-026-26834-2","volume":"26","author":"Q Yi","year":"2026","unstructured":"Yi Q, Yang N, Zeng L, Huang L, Zou K, Chen J, et al. How to alleviate the shortage: a scoping review of prevention and management of global drug shortages. BMC Public Health [Internet]. 2026, Mar, 3;26(1):1149. Available from: https:\/\/doi.org\/10.1186\/s12889-026-26834-2.","journal-title":"BMC Public Health"},{"key":"14893_CR58","doi-asserted-by":"publisher","first-page":"106914","DOI":"10.1016\/j.econmod.2024.106914","volume":"142","author":"Z Mrabet","year":"2025","unstructured":"Mrabet Z, Alsamara M, Mimouni K, Awwad A. Do supply chain pressures affect consumer prices in major economies? New evidence from time-varying causality analysis. Econ Model [Internet]. 2025, Jan;142:106914. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264999324002712.","journal-title":"Econ Model"},{"issue":"5","key":"14893_CR59","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18773\/austprescr.2024.045","volume":"47","author":"T Simpson","year":"2024","unstructured":"Simpson T, Yik J. Managing medicine shortages. Aust Prescr. 2024, Oct, 22;47(5):148\u201352. https:\/\/doi.org\/10.18773\/austprescr.2024.045.","journal-title":"Aust Prescr"},{"key":"14893_CR60","doi-asserted-by":"crossref","unstructured":"Aivazi MA, Rasekh HR, Peikanpour M, Peiravian F, Esmaeili S, Zarei L. The COVID-19 pandemic and the resilience of the pharmaceutical supply chain: lessons from past experiences and strategies for the Future. Iran J Pharm Res [Internet]. 2024, Nov, 5;23(1). Available from: https:\/\/brieflands.com\/journals\/ijpr\/articles\/152723.","DOI":"10.5812\/ijpr-152723"},{"issue":"4","key":"14893_CR61","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1136\/ejhpharm-2020-002341","volume":"27","author":"N Miljkovi\u0107","year":"2020","unstructured":"Miljkovi\u0107 N, Batista A, Polidori P, Kohl S, Hor\u00e1k P. Results of EAHP\u2019s 2019 medicines shortages survey. Eur J Hosp Pharm [Internet]. 2020, Jul;27(4):202\u201308. Available from: https:\/\/doi.org\/10.1136\/ejhpharm-2020-002341.","journal-title":"Eur J Hosp Pharm"},{"key":"14893_CR62","unstructured":"European Federation of Pharmaceutical Industries and Associations. Medicine shortages: EFPIA proposal for action [Internet]. Brussels; 2024 Dec [cited 2026 Feb 1]. https:\/\/www.efpia.eu\/media\/676845\/medicine-shortages-efpia-proposal-for-action.pdf."},{"key":"14893_CR63","doi-asserted-by":"publisher","unstructured":"Bochenek T, Abilova V, Alkan A, Asanin B, de Miguel Beriain I, Besovic Z, et al. Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian countries. Front Pharmacol. 2018, Jan, 18;8. https:\/\/doi.org\/10.3389\/fphar.2017.00942.","DOI":"10.3389\/fphar.2017.00942"},{"issue":"8","key":"14893_CR64","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.sapharm.2023.05.007","volume":"19","author":"C Bade","year":"2023","unstructured":"Bade C, Olsacher A, Boehme P, Truebel H, Fehring L. Reasons for supply side driven drug shortages \u2013 a mixed-methods study on first-level, higher-level, and root causes from the perspective of marketing authorization holders. Res Soc Adm Pharm. 2023, Aug;19(8):1218\u201327. https:\/\/doi.org\/10.1016\/j.sapharm.2023.05.007.","journal-title":"Res Soc Adm Pharm"},{"key":"14893_CR65","doi-asserted-by":"publisher","unstructured":"Sarnola K, Kari H, Koskinen H. Medicine shortages: product life cycle phases and characteristics of medicines in short supply\u2014A register study. Front Pharmacol. 2022, Jun, 27;13. https:\/\/doi.org\/10.3389\/fphar.2022.943249.","DOI":"10.3389\/fphar.2022.943249"},{"key":"14893_CR66","unstructured":"European Commission. Addressing medicine shortages in the EU [Internet]. 2023. Available from: https:\/\/commission.europa.eu\/system\/files\/2023-10\/Communication_medicines_shortages_EN_0.pdf."},{"key":"14893_CR67","unstructured":"Commission E. Commission proposes critical medicines act to bolster the supply of critical medicines in the EU [Internet]. Brussels; 2025. Available from: https:\/\/ec.europa.eu\/commission\/presscorner\/api\/files\/document\/print\/en\/ip_25_733\/IP_25_733_EN.pdf."},{"issue":"3","key":"14893_CR68","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1017\/S1744133111000090","volume":"6","author":"PG Kanavos","year":"2011","unstructured":"Kanavos PG, Vandoros S. Determinants of branded prescription medicine prices in OECD countries. HEPL [Internet]. 2011, Jul, 11;6(3):337\u201367. Available from: https:\/\/www.cambridge.org\/core\/product\/identifier\/S1744133111000090\/type\/journal_article.","journal-title":"HEPL"},{"issue":"2","key":"14893_CR69","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5639\/gabij.2012.0102.020","volume":"1","author":"S Vogler","year":"2012","unstructured":"Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries\u2500an overview. GaBI J [Internet]. 2012, May, 15;1(2):93\u2013100. Available from: http:\/\/www.gabi-journal.net\/the-impact-of-pharmaceutical-pricing-and-reimbursement-policies-on-generics-uptake-implementation-of-policy-options-on-generics-in-29-european-countries-an-overview.html.","journal-title":"GaBI J"},{"key":"14893_CR70","doi-asserted-by":"publisher","first-page":"1200641","DOI":"10.3389\/fphar.2023.1200641","volume":"14","author":"C Francois","year":"2023","unstructured":"Francois C, Gawlik G, Mestre-Ferrandiz J, Pana A, Perelman J, Yfantopoulos J, et al. New pricing models for generic medicines to ensure long-term sustainable competition in Europe. Front Pharmacol [Internet]. 2023;14:1200641. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37876734.","journal-title":"Front Pharmacol"},{"key":"14893_CR71","unstructured":"Watt A. Exploring drug shortages in European markets: the causes, analysis, and response. Pharmaceutical technology [Internet]. 2024, Available from: https:\/\/www.pharmaceutical-technology.com\/analyst-comment\/exploring-drug-shortages-european-markets\/?cf-view."},{"issue":"1","key":"14893_CR72","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2991\/chi.d.190321.003","volume":"1","author":"R Gupta","year":"2019","unstructured":"Gupta R, Savani U, Gatwood K, Culos K. The recurring problem of drug shortages\u2014how do we overcome it? [Internet]. Clin Hematol Int. 2019, Mar;1(1):75\u201377. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34595413.","journal-title":"Clin Hematol Int"},{"key":"14893_CR73","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ahj.2016.02.004","volume":"175","author":"BN Reed","year":"2016","unstructured":"Reed BN, Fox ER, Konig M, Jackevicius CA, Masoudi FA, Rabinstein AA, et al. The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action. Am Heart J [Internet]. 2016, May;175:130\u201341. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287031600048X.","journal-title":"Am Heart J"},{"key":"14893_CR75","doi-asserted-by":"publisher","unstructured":"Vogler S, Zimmermann N, Haasis MA, Knoll V, Espin J, Mantel-Teeuwisse AK, et al. Innovations in pharmaceutical policies and learnings for sustainable access to affordable medicines. J Pharm Policy Pract. 2024, Apr 30;17(sup1). [Internet]. Available from: https:\/\/doi.org\/10.1080\/20523211.2024.2335492.","DOI":"10.1080\/20523211.2024.2335492"},{"issue":"3","key":"14893_CR76","doi-asserted-by":"publisher","first-page":"145","DOI":"10.7326\/M16-1432","volume":"167","author":"V Dave C","year":"2017","unstructured":"Dave C V, Kesselheim AS, Fox ER, Qiu P, Hartzema A. High generic drug prices and market competition. Ann Intern Med [Internet]. 2017, Aug, 1;167(3):145\u201351. Available from: https:\/\/doi.org\/10.7326\/M16-1432.","journal-title":"Ann Intern Med"},{"issue":"3","key":"14893_CR77","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/1468-0009.12517","volume":"99","author":"RG Frank","year":"2021","unstructured":"Frank RG, Mcguire TG, Nason I. The Evolution of supply and demand in markets for generic drugs. Milbank Q [Internet]. 2021, Sep;99(3):828\u201352. Available from: https:\/\/doi.org\/10.1111\/1468-0009.12517.","journal-title":"Milbank Q"},{"key":"14893_CR78","doi-asserted-by":"publisher","unstructured":"Shukar S, Zahoor F, Hayat K, Saeed A, Gillani AH, Omer S, et al. Drug shortage: causes, impact, and mitigation strategies. Front Pharmacol. 2021, Jul, 9;12;12. https:\/\/doi.org\/10.3389\/fphar.2021.693426.","DOI":"10.3389\/fphar.2021.693426"},{"key":"14893_CR79","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2147\/CEOR.S140063","volume":"9","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Drug tendering: drug supply and shortage implications for the uptake of biosimilars. CEOR [Internet]. 2017, Sep;9:573\u201384. Available from: https:\/\/www.dovepress.com\/drug-tendering-drug-supply-and-shortage-implications-for-the-uptake-of-peer-reviewed-article-CEOR.","journal-title":"CEOR"},{"key":"14893_CR80","unstructured":"Gawronski MARCIN, Troein PER, Newton MAX. From regulated prices to prices set in tenders [Internet]. IQVIA Expertise. 2022. Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/tendering-landscape-in-europe-whitepaper-19-10-orb3270.pdf."},{"issue":"2","key":"14893_CR81","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40258-021-00705-w","volume":"20","author":"NX Nguyen","year":"2022","unstructured":"Nguyen NX, Sheingold SH, Tarazi W, Bosworth A. Effect of competition on generic drug prices. Appl Health Econ Health Policy [Internet]. 2022, Mar, 13;20(2):243\u201353. Available from: https:\/\/link.springer.com\/10.1007\/s40258-021-00705-w.","journal-title":"Appl Health Econ Health Policy"},{"key":"14893_CR82","doi-asserted-by":"publisher","unstructured":"Gronde TVD, Uyl-de Groot CA, Pieters T. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: a systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS One [Internet]. 2017, Aug, 16;12(8):e0182613. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0182613. Mihalopoulos","DOI":"10.1371\/journal.pone.0182613"},{"issue":"11","key":"14893_CR83","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jval.2018.04.1826","volume":"21","author":"V Dave C","year":"2018","unstructured":"Dave C V, Pawar A, Fox ER, Brill G, Kesselheim AS. Predictors of drug shortages and association with generic drug prices: a retrospective cohort study. Value Health [Internet]. 2018, Nov;21(11):1286\u201390. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830151832148X.","journal-title":"Value Health"},{"key":"14893_CR84","doi-asserted-by":"crossref","unstructured":"R\u00e9muzat C, Urbinati D, Mzoughi O, El Hammi E, Belgaied W, Toumi M. Overview of external reference pricing systems in Europe. J mark access heal policy [Internet]. 2015. 3. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27123181.","DOI":"10.3402\/jmahp.v3.27675"},{"key":"14893_CR85","unstructured":"Romanian Ministry of Health. Order no. 1345 of 24 November 2016 regarding the daily reporting of stocks and commercial operations with medicinal products for human use [Internet]. 2016. Available from: https:\/\/www.anm.ro\/_\/ORDINE\/ORDINNr1345din24nov2016_raportarezilnicastocuri.pdf. Bucharest."},{"key":"14893_CR86","unstructured":"Ministry of Health of Romania. Order No. 269\/2017 regarding the obligation to ensure adequate and continuous stocks [Internet]. 2017. Available from: https:\/\/www.colegfarm.ro\/userfiles\/file\/OMSBucharest269_2017_obligstocuriadecvatesicontinue.pdf."},{"key":"14893_CR87","unstructured":"Romanian Parliament. Law No. 95\/2006 of 14 April 2006 on healthcare reform [republished].Official Monitor of Romania. Part I. 2015;28(652). https:\/\/www.anm.ro\/_\/LEGI%20ORDONANTE\/Legea%2095-2006.pdf."},{"key":"14893_CR88","unstructured":"European Parliament and Council of the European Union. Directive 2001\/83\/EC of 6 November 2001 on the community code relating to medicinal products for human use. Official journal of the European communities. 2001."},{"key":"14893_CR89","unstructured":"Romanian Ministry of Health. Order no. 85 of 7 February 2013 approving the norms for the implementation of article 703 (1) and (2) of Law no. 95\/2006 on healthcare reform regarding medicinal products used to meet special needs [Internet]. 2013. Available from: https:\/\/www.anm.ro\/_\/ORDINE\/ORDIN85_2013modifsicompletatin2016.pdf."},{"key":"14893_CR90","unstructured":"Romanian Ministry of Health. Order no. 1540 of 13 August 2021 approving the norms for the implementation of article 883 of Law no. 95\/2006 on healthcare reform regarding the authorization of placing on the market of medicinal products needed for public health reasons [Internet]. Bucharest; 2021. Available from: https:\/\/www.anm.ro\/_\/ORDINE\/Ordin1540-2021.pdf."},{"key":"14893_CR91","doi-asserted-by":"publisher","unstructured":"Shafiq N, Pandey AK, Malhotra S, Holmes A, Mendelson M, Malpani R, et al. Shortage of essential antimicrobials: a major challenge to global health security. BMJ Glob Health [Internet]. 2021, Nov, 2;6(11):e006961. Available from: https:\/\/doi.org\/10.1136\/bmjgh-2021-006961.","DOI":"10.1136\/bmjgh-2021-006961"},{"key":"14893_CR92","doi-asserted-by":"publisher","unstructured":"Looi M-K. EU medicine shortages hit record high last year and more disruption could be coming, report warns. BMJ [Internet]. 2025, Sep;390(390):r1965. Available from: https:\/\/doi.org\/10.1136\/bmj.r1965.","DOI":"10.1136\/bmj.r1965"},{"key":"14893_CR93","doi-asserted-by":"crossref","unstructured":"Kawalec P, Tesar T, Vostalova L, Draganic P, Manova M, Savova A, et al. Pharmaceutical regulation in Central and Eastern European countries: a current review. Front Pharmacol [Internet]. 2017, Dec, 18;8. Available from: http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00892\/full.","DOI":"10.3389\/fphar.2017.00892"},{"key":"14893_CR94","unstructured":"The European Court of Auditors. Critical shortages of medicines - EU measures were of added value, but structural problems remain [Internet]. 2025. Available from: https:\/\/www.eca.europa.eu\/ECAPublications\/SR-2025-19\/SR-2025-19_EN.pdf."},{"issue":"1","key":"14893_CR95","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1017\/S1744133120000109","volume":"16","author":"D Danieli","year":"2021","unstructured":"Danieli D. Excessive pricing in the pharmaceutical industry: adding another string to the bow of EU competition law. HEPL. 2021, Jan;16(1):64\u201375. https:\/\/doi.org\/10.1017\/S1744133120000109.","journal-title":"HEPL"},{"issue":"1","key":"14893_CR96","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10198-019-01116-4","volume":"21","author":"P Kanavos","year":"2020","unstructured":"Kanavos P, Fontrier A-M, Gill J, Efthymiadou O. Does external reference pricing deliver what it promises? Evidence on its impact at national level. Eur J Health Econ [Internet]. 2020, Feb, 3;21(1):129\u201351. Available from: https:\/\/doi.org\/10.1007\/s10198-019-01116-4.","journal-title":"Eur J Health Econ"},{"key":"14893_CR97","unstructured":"European Commission. Cost-containment policies in public pharmaceutical spending in the EU [Internet]. Brussels; 2012. Available from: https:\/\/ec.europa.eu\/economy_finance\/publications\/economic_paper\/2012\/pdf\/ecp_461_en.pdf."},{"issue":"14","key":"14893_CR98","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/ajhp\/zxab152","volume":"78","author":"I Liu","year":"2021","unstructured":"Liu I, Colmenares E, Tak C, Vest M-H, Clark H, Oertel M, et al. Development and validation of a predictive model to predict and manage drug shortages. Am J Health-System Pharm [Internet]. 2021, Jul, 9;78(14):1309\u201316. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33821926.","journal-title":"Am J Health-System Pharm [Internet]"},{"issue":"2","key":"14893_CR99","doi-asserted-by":"publisher","first-page":"85","DOI":"10.52937\/hira.25.5.2.e4","volume":"5","author":"I Song","year":"2025","unstructured":"Song I. Predictive analytics on drug shortages and Future challenges: a review. HIRA Res [Internet]. 2025, Nov, 30;5(2):85\u201397. Available from: https:\/\/www.hira-research.or.kr\/journal\/view.html?doi=10.52937\/hira.25.5.2.e4.","journal-title":"HIRA Res"},{"issue":"6","key":"14893_CR100","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/deci.12583","volume":"53","author":"KE van Oorschot","year":"2022","unstructured":"van Oorschot KE, Van Wassenhove LN, Jahre M, Selviaridis K, de VriesH, de Vries H. Drug shortages: a systems view of the current state. Decis Sci [Internet]. 2022, Dec, 17;53(6):969\u201384. Available from: https:\/\/doi.org\/10.1111\/deci.12583.","journal-title":"Decis Sci"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14893-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14893-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14893-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:03:40Z","timestamp":1787231020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14893-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14893"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14893-5","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients were not involved in the design, conduct, reporting, or dissemination plans of this research.","order":2,"name":"Ethics","label":"Patient and public involvement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.A. received consultancy or speakers\u2019 fees in the past from Merck, UCB, Sandoz, Abbvie, Zentiva, Teva, Laropharm, CEGEDIM, Angelini, Biessen Pharma, Hofigal, AstraZeneca, and Stada. All other authors report no conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1169"}}